Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Overview

NASDAQ:QNRX - US74907L4095 - ADR

7.5599 USD
-0.06 (-0.85%)
Last: 9/5/2025, 8:00:01 PM

QNRX Key Statistics, Chart & Performance

Key Statistics
52 Week High54.95
52 Week Low5.01
Market Cap4.45M
Shares588.20K
Float586.77K
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-41.48
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05
IPO11-01 1989-11-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


QNRX short term performance overview.The bars show the price performance of QNRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

QNRX long term performance overview.The bars show the price performance of QNRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of QNRX is 7.5599 USD. In the past month the price increased by 9.41%. In the past year, price decreased by -71.94%.

QUOIN PHARMACEUTICALS LT-ADR / QNRX Daily stock chart

QNRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.7 368.47B
AMGN AMGEN INC 12.81 150.41B
GILD GILEAD SCIENCES INC 14.91 143.15B
VRTX VERTEX PHARMACEUTICALS INC 23.21 100.83B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.96B
REGN REGENERON PHARMACEUTICALS 12.16 58.81B
ARGX ARGENX SE - ADR 81.97 46.50B
ONC BEONE MEDICINES LTD-ADR 6.03 40.92B
INSM INSMED INC N/A 30.88B
BNTX BIONTECH SE-ADR N/A 24.89B
NTRA NATERA INC N/A 22.95B
BIIB BIOGEN INC 8.87 20.81B

About QNRX

Company Profile

QNRX logo image Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Company Info

QUOIN PHARMACEUTICALS LT-ADR

23 Hata'as Street

Kfar Saba IL

CEO: Shai Yarkoni

Employees: 3

QNRX Company Website

QNRX Investor Relations

Phone: 97299741444

QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ

What is the stock price of QUOIN PHARMACEUTICALS LT-ADR today?

The current stock price of QNRX is 7.5599 USD. The price decreased by -0.85% in the last trading session.


What is the ticker symbol for QUOIN PHARMACEUTICALS LT-ADR stock?

The exchange symbol of QUOIN PHARMACEUTICALS LT-ADR is QNRX and it is listed on the Nasdaq exchange.


On which exchange is QNRX stock listed?

QNRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for QUOIN PHARMACEUTICALS LT-ADR stock?

8 analysts have analysed QNRX and the average price target is 28.05 USD. This implies a price increase of 271.04% is expected in the next year compared to the current price of 7.5599. Check the QUOIN PHARMACEUTICALS LT-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is QUOIN PHARMACEUTICALS LT-ADR worth?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a market capitalization of 4.45M USD. This makes QNRX a Nano Cap stock.


How many employees does QUOIN PHARMACEUTICALS LT-ADR have?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) currently has 3 employees.


What are the support and resistance levels for QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a support level at 7.47 and a resistance level at 7.74. Check the full technical report for a detailed analysis of QNRX support and resistance levels.


Should I buy QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock pay dividends?

QNRX does not pay a dividend.


When does QUOIN PHARMACEUTICALS LT-ADR (QNRX) report earnings?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2025-11-05.


What is the Price/Earnings (PE) ratio of QUOIN PHARMACEUTICALS LT-ADR (QNRX)?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-41.48).


What is the Short Interest ratio of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

The outstanding short interest for QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 1.05% of its float. Check the ownership tab for more information on the QNRX short interest.


QNRX Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to QNRX. When comparing the yearly performance of all stocks, QNRX is a bad performer in the overall market: 95.84% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

QNRX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to QNRX. QNRX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QNRX Financial Highlights

Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -41.48. The EPS increased by 78.57% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -136.54%
ROE -476.97%
Debt/Equity 1.03
Chartmill High Growth Momentum
EPS Q2Q%53.99%
Sales Q2Q%N/A
EPS 1Y (TTM)78.57%
Revenue 1Y (TTM)N/A

QNRX Forecast & Estimates

8 analysts have analysed QNRX and the average price target is 28.05 USD. This implies a price increase of 271.04% is expected in the next year compared to the current price of 7.5599.


Analysts
Analysts82.5
Price Target28.05 (271.04%)
EPS Next Y65.24%
Revenue Next YearN/A

QNRX Ownership

Ownership
Inst Owners1.6%
Ins Owners7.08%
Short Float %1.05%
Short Ratio1.29